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Abstract
Smoking is a potentially causal behavioral risk factor for type 2 diabetes (T2D), but not all
smokers develop T2D. It is unknown whether genetic factors partially explain this variation.
We performed genome-environment-wide interaction studies to identify loci exhibiting
potential interaction with baseline smoking status (ever vs. never) on incident T2D and fast-
ing glucose (FG). Analyses were performed in participants of European (EA) and African
ancestry (AA) separately. Discovery analyses were conducted using genotype data from
the 50,000-single-nucleotide polymorphism (SNP) ITMAT-Broad-CARe (IBC) array in 5
cohorts from from the Candidate Gene Association Resource Consortium (n = 23,189).
Replication was performed in up to 16 studies from the Cohorts for Heart Aging Research in
Genomic Epidemiology Consortium (n = 74,584). In meta-analysis of discovery and replica-
tion estimates, 5 SNPs met at least one criterion for potential interaction with smoking on
incident T2D at p<1x10-7 (adjusted for multiple hypothesis-testing with the IBC array). Two
SNPs had significant joint effects in the overall model and significant main effects only in
one smoking stratum: rs140637 (FBN1) in AA individuals had a significant main effect only
among smokers, and rs1444261 (closest gene C2orf63) in EA individuals had a significant
main effect only among nonsmokers. Three additional SNPs were identified as having
potential interaction by exhibiting a significant main effects only in smokers: rs1801232
(CUBN) in AA individuals, rs12243326 (TCF7L2) in EA individuals, and rs4132670
(TCF7L2) in EA individuals. No SNP met significance for potential interaction with smoking
on baseline FG. The identification of these loci provides evidence for genetic interactions
with smoking exposure that may explain some of the heterogeneity in the association
between smoking and T2D.
Introduction
Cigarette smoking and type 2 diabetes (T2D) are both costly burdens on human health in the
United States and worldwide [1–4]. These public health threats are interrelated: smoking is a
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dose-dependent risk factor for incident T2D, independent of potential confounders including
physical activity and body-mass index (BMI) [5]. Moreover, smoking raises fasting glucose
(FG) [6, 7] itself a predictor of incident T2D [8–10]. Experimental studies point to plausible
biologic mechanisms through which smoking may directly cause T2D, such as the impairment
of insulin-mediated glucose transport [11], insulin sensitivity [12–18], and insulin secretion
[19–21].
Not every individual who smokes develops T2D, and the relationship between smoking and
T2D has considerable heterogeneity. This variation suggests the possibility of genetic modifiers
of the effect of smoking on T2D risk. Genetic studies of smoking behavior [22–27] and T2D
and FG [28–36] have separately uncovered hundreds of loci associated with these traits, but no
genome-wide association study to date has sought genetic loci that modify the relationships
among them. We conducted gene-environment-wide interaction studies (GEWIS) to identify
potential gene-by-smoking interactions for both T2D risk and FG among 97,773 cohort study
participants of European (EA) and African ancestry (AA).
Materials and methods
Study design overview
We conducted two-stage GEWIS analyses to identify potential genotype-smoking interactions
for two related traits: incident T2D and baseline FG. Smoking status was dichotomized as indi-
viduals who were current or former smokers at baseline (ever smokers) and individuals with
no current or past smoking history (never smokers). The discovery stage analyses leveraged
data from 5 cohort studies from the Candidate Gene Association Resource (CARe) Consor-
tium. Single-nucleotide polymorphisms (SNPs) that had significant association with a trait in
meta-analysis of the discovery cohort data were carried forward for replication in up to 16
cohorts from the Cohorts for Heart & Aging Research in Genomic Epidemiology (CHARGE)
Consortium Gene-Lifestyle Interactions Working Group and combined discovery plus repli-
cation meta-analysis. The Partners Human Research Committee approved this study.
Cohort descriptions and sample sizes
In the discovery stage, we analyzed data from five cohorts from the CARe Consortium [37]:
The Atherosclerosis Risk in Communities Study (ARIC), the Coronary Artery Risk Develop-
ment in Young Adults Study (CARDIA), the Cardiovascular Health Study (CHS), the Fra-
mingham Heart Study (FHS), and the Multi-Ethnic Study of Atherosclerosis (MESA) (S1
Table) [37]. The total sample size of these five discovery stage cohorts was 23,189, including
18,365 European American (EA) and 4,824 African American (AA). Among 23,189 CARe par-
ticipants, 10,120 were never smokers and 13,069 were ever smokers, as assessed at their base-
line study examinations. In the replication stage, 74,584 individuals from up to 16 cohorts in
the Cohorts for Heart & Aging Research in Genomic Epidemiology (CHARGE) Consortium
Gene-Lifestyle Interactions Working Group were included, comprised of 61,397 EA partici-
pants and 13,187 AA participants. A total of 40,819 and 33,765 were never and ever smokers,
respectively (S1 Table) [38]. All five discovery cohorts contributed data for both traits of inter-
est: incident T2D and baseline glucose. Eight replication cohorts contributed data for the inci-
dent T2D analyses, and 15 replication cohorts contributed data for the fasting glucose analyses
(S1 Table). Across the discovery and replication cohorts, there were 4,040 T2D cases and
48,521 controls among EA participants and 717 cases and 7,180 controls among AA
participants.
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Description of phenotype and covariates
We considered two traits: incident T2D and baseline FG. Presence of T2D was defined by any
one of the following criteria: 1) FG� 7 mmol/L; 2) on diabetes treatment or HbA1c� 6.5%;
3) 2-hr oral glucose tolerance test�11.1 mmol/L; 4) random/non-fasting glucose� 11.1
mmol/L; 5) physician diagnosis of diabetes; or 6) self-reported diabetes (S1 Table). For the
analysis of incident T2D, participants meeting the T2D definition at baseline were excluded.
For the remaining participants, time-to-T2D was defined as the time from the date of the base-
line examination to the date the T2D case definition was met or, for controls, to the last date of
follow-up. For the FG analyses, participants with T2D were excluded, and FG was identified
from the baseline measurement taken after a fast of 8 hours or more (S1 Table).
Genotyping
Participants in the CARe Consortium were genotyped with the custom ITMAT-Broad-CARe
(IBC) genotyping array (IBC v2 chip), which contains around 50,000 SNPs across 2,000 loci selected
for their relationship to cardiovascular disease and its risk factors. Details about SNP selection crite-
ria and genotyping quality control (QC) procedures have been described [39]. Details of the geno-
typing methods used in the individual CHARGE replication cohorts are presented in S1 Table.
Cohort-level statistical analysis
We performed ancestry-stratified analyses for the two traits within each discovery and replica-
tion cohort. Smoking-stratified analyses were also conducted separately in each of the four
trait-ancestry combinations. In total, we performed four models for each of four trait-ancestry
combinations: an interaction model regressing the trait (incident T2D or FG) on the genetic
variant, smoking status, and their interaction term (Model 1); a main effect-only model
(Model 2); and two smoking-stratified models, regressing incident T2D or FG on the genetic
variant predictor in smokers (Model 3) and nonsmokers (Model 4) separately. All models
were covariate-adjusted as described below.
We analyzed incident T2D using Cox proportional hazards models and robust sandwich vari-
ance estimators. For cohorts with related individuals, each family was treated as a cluster. Models
were adjusted for age, BMI, and the genetic principal components associated with incident T2D
at p<0.05. Models were not adjusted for sex in the discovery cohorts due to insufficient numbers
of incident T2D cases in all sex/ancestry categories; models were conducted with or without sex
adjustment in the replication analyses, depending on the sample size of stratified samples.
For baseline FG, we used linear regression for cohorts with independent samples. For
cohorts with family structures, we used generalized estimating equations (GEE) to obtain esti-
mates for Model 1, assuming an exchangeable working correlation matrix, since the GEE
model with an interaction term provides robust standard error estimates. Linear mixed effects
models were used to evaluate Models 2–4, with random effects to account for family structures.
All FG analyses were adjusted for age, sex, BMI and the genetic principal components associ-
ated with FG at p<0.05.
Meta-analysis
For both traits, we obtained summary statistics of association from each cohort and then con-
ducted fixed-effect meta-analysis to combine the results. For each trait (incident T2D and FG),
we meta-analyzed the results across the cohorts using inverse variance weighting, in EA and
AA separately. We defined a potential interaction effect between a locus and smoking if at least
one of the following criteria was met: 1) significant SNP-by-smoking interaction; 2) significant
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joint 2-degree-of-freedom test of interaction and main effect, excluding SNPs with significant
main effects; or 3) significant SNP effect in only one smoking stratum (never or ever smokers).
In the discovery stage, significance was defined as p<10−3; we selected all SNPs significant for
at least one of these 3 criteria as candidate SNPs. Candidate SNPs were then carried forward
for replication in the cohorts of the CHARGE Consortium. We performed meta-analyses with
summary statistics from the discovery and replication stages, defining significance as
p< 1×10−7 for at least one of the 3 criteria above. We selected this significance threshold to
conservatively account for multiple hypothesis-testing, since p< 2×10−6 is commonly used for
studies with the 50,000-SNP IBC genotyping array [40, 41] and we performed a total of 20 tests
(5×2×2), comprised of 5 models (main effect, interaction effect, joint effect, and 2 smoking
stratified analyses) for 2 traits in 2 ancestry groups for each variant.
Power calculations
Power analyses were performed for a significance level of α = 1x10-7 to detect a potential inter-
action effect on both T2D and FG. For T2D, we approximated the power analysis to detect
potential interaction with logistic regression. Under the assumption that the effect size for
interaction is similar to the effect size of the main SNP effect, the sample sizes of 4,040 EA
cases and 717 AA cases enabled 80% power to detect an odds ratio (OR) of 1.39 in EA and 1.76
in AA, using an unmatched population-based case-control design under an additive genetic
model and assuming MAF = 0.3 with 10% T2D prevalence and 30% smoking prevalence. For
FG, the sample sizes of 58,783 EA and 17,675 AA enabled 80% power to detect SNPs with R2GE
� 0.06% EA and� 0.2% AA for SNP�interaction effect in interaction testing, using an additive
genetic model and assuming variants with R2G = 0.1%
Conditional analysis
We performed conditional analyses for the two significant variants identified in TCF7L2 in the
T2D analysis. In each corhort, we ran the joint (Model 1) and main effect only models (Model
2) described above for rs4132670 conditioned on the most significant variant, rs12243326. The
cohort-level conditional analyses were meta-analyzed to obtain overall summary statistics.
Locus characterization
We queried the National Human Genome Research Institute (NHGR)–European Bioinfor-
matics Institute (EBI) GWAS Catalog for any published trait associations with SNPs achieve-
ing GEWIS significance in this study [42]. We also examined the overlap between these SNPs
and genomic annotation using HaploReg [43], which collects information from multiple func-
tional annotation resources and reports information about queried SNPs such as genomic
position, protein-coding impact, available expression quantitative trait locus (eQTL) data,
overlap with known transcription factor binding sites or predicted transcription factor binding
motifs, and overlap with DNAse hypersensitivity sites or histone marks associated with pro-
moters and enhancers. In addition, we queried each GEWIS-significant SNP in RegulomeDB
[44], a database of known and predicted regulatory elements in human intergenic regions, and
in the Genotype-Tissue Expression project (GTEx) portal to obtain additional eQTL data [45].
Results
Incident T2D
A total of 371 SNPs met the p<10−3 threshold for incident T2D in discovery stage analyses and
were carried forward to the replication stage. Of these, 171 were identified among EA
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individuals and 200 were identified in AA individuals; no SNP was identified in both sub-
groups (S2 Table).
In meta-analysis of discovery and replication estimates, five SNPs were significant for
potential interaction at p<1×10−7 by at least one criterion, and two of these were significant by
two criteria (Table 1). Two SNPs had significant joint effects in the overall model and signifi-
cant main effects in only one smoking stratum in stratified analyses: rs140637 (FBN1 on chro-
mosome 15, MAF = 0.13) among AA smokers and rs1444261 (closest gene C2orf63 on
chromosome 2, MAF = 0.05) among EA nonsmokers. Among AA participants, rs140637 in
FBN1 was consistently associated with lower T2D risk among smokers only. In the discovery,
replication, and combined stage meta-analyses, the per-allele HR for T2D was 0.34 (95%
CI = 0.23, 0.51, p = 8.8 x 10−8), 0.39 (95% CI = 0.20, 0.76, p = 5.3 x 10−3), and 0.34 (95%
CI = 0.24, 0.49, p = 2.9 x 10−9), respectively. For rs1444261 near C2orf63, in the discovery
stage, the per-allele hazard ratio (HR) for T2D was 0.64 (95% CI = 0.51, 0.82, p = 3.7 x 10−4)
among never smokers, but the direction of effect reversed in the replication stage (HR 1.24,
95% CI = 1.18, 1.29, p = 3.1 x 10−21) and overall meta-analysis (HR 1.21, 95% CI = 1.16, 1.26,
p = 5.1 x 10−18).
Three additional SNPs were significant by one criterion only, namely, significant main
effect only among smokers in stratified analyses. Among EA smokers, these included
rs4132670 (MAF = 0.30) and rs12243326 (MAF = 0.26), both in the well-described T2D-asso-
ciated gene TCF7L2. Among AA smokers, rs1801232, a missense SNP in CUBN on chromo-
some 10 (MAF = 0.12), exhibited a significant main effect (S1 Fig). We observed the largest
effect size for potential interaction at this CUBNmissense variant, where the per-allele hazard
ratio for T2D was 2.78 (95% CI = 1.92, 4.03, p = 5.5 x 10−8) among smokers and 1.01 (95%
CI = 0.58, 1.77, p = 0.97) among non-smokers (pjoint = 1.3 x 10−7).
We provide regional plots for rs1224336 in TCF7L2 in Fig 1 because the discovery stage,
replication stage, and combined meta-analysis showed chip-wide significance for joint effect
and main effect in smokers among EA participants. Among smokers and non-smokers, the
per-allele HR for T2D in the discovery plus replication meta-analysis was 0.90 (95% CI = 0.86,
0.93, p = 3.2 x 10−8) and 0.96 (95% CI = 0.94, 0.98, p = 7.5 x 10−5), respectively. In analyses con-
ditioned on rs12243326, rs4132670 (r2 = 0.72 and D’ = 0.95) was no longer significantly associ-
ated with main effect with T2D (all p>0.4).
Fasting glucose
In the discovery stage analysis for baseline FG among 23,189 participants, we observed 343
SNPs meeting the significance threshold of p<10−3 in at least one of the three planned strate-
gies for potential interaction: 175 among EA participants and 168 among AA participants.
Again, no locus was identified in both ancestral subgroups (S3 Table). Meta-analysis identified
rs4132670 in TCF7L2 (MAF = 0.30) as the most significant variant for the joint effect analysis
in EA participants only (p = 4.6 x10-8), but it did not meet the criteria for potential interaction
because its main effect association was also significant (p = 2.8 ×10−10)
Locus characterization
Of the five SNPs at four loci achieving statistical significance in the GEWIS analyses (TCF7L2,
CUBN, FBN1, and near C2orf63), only rs12243326, an intronic variant in TCF7L2, has trait
associations in the NHGRI-EBI GWAS Catalog, with the glycemic traits of 2-hour glucose
challenge, fasting insulin, FG, and BMI interaction on FG. Of the five SNPs at four loci achiev-
ing statistical significance in the GEWIS analyses (TCF7L2, CUBN, FBN1, and near C2orf63),
only the missense CUBN SNP is a nonsynonymous variant. All five GEWIS-significant SNPs
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overlap with at least one promoter or enhancer regulatory mark in at least one tissue with rele-
vance to diabetes, including brain, muscle, gastrointestinal tract, pancreas, adipose, and liver
(S4 Table). SNPs at three of the four loci (C2orf63, TCF7L2, and CUBN) had eQTL associa-
tions, and SNPs at all four loci overlap with either a DNA-binding site or alter a predicted
DNA-binding motif (S4 Table).
Discussion
Using data from 61,164 participants from 19 cohort studies, we performed two GEWIS to
identify potential SNP-by-smoking interactions in the risk of T2D and baseline FG. We identi-
fied potential interactions between smoking status and five SNPs at or near four genes
(TCF7L2, CUBN, C2orf63 (closest gene), and FBN1) on the risk of incident T2D in EA or AA
participants. We identified no significant SNP-smoking interactions for FG.
The relationship between smoking and T2D is complex and likely results from both con-
founding and true causal relationships [46]. Smokers are less likely to be physically active [47]
Fig 1. Regional plots for the association of rs1224336 in TCF7L2 with T2D.
https://doi.org/10.1371/journal.pone.0230815.g001
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and more likely to have unhealthier dietary intake [48, 49]. Still, a meta-analysis of 25 prospec-
tive studies by Willi found that smokers had a risk ratio for incident T2D of 1.44 (95% CI 1.31,
1.58) over 5 to 30 years of follow-up after adjustment, when possible, for BMI, physical activity,
and other potential confounders. Individuals with the greatest smoking exposure had the
greatest T2D risk [5]. Moreover, experimental data suggest plausible causal pathways between
smoking and T2D. First, smoking generates reactive oxygen species (ROS) [50], which
decrease in vitro insulin-mediated glucose transport [11]. Second, smoking stimulates the sym-
pathetic system and cortisol release, increasing central obesity and insulin resistance [12–14].
Nicotine may mediate these pathways, as it increases insulin resistance [15–18], possibly
through increased ROS production and TNF-α expression [18]. Nicotine also decreases insu-
lin secretion from pancreatic β-cells [19], and fetal and neonatal exposure to nicotine results in
β-cell dysfunction and apoptosis [20,21]. GEWIS might help elucidate additional biological
pathways to explain the relationship between smoking and T2D. A linkage disequilibrium
regression score study of 276 genetic correlations among 24 traits found no genetic correlation
between smoking status and either T2D or FG [51], but one small study has reported that
smoking status accounted for 22% of the gene-environment variance in β-cell function, as
measured by the homeostatic model assessment (HOMA-β) [52].
We observed the largest potential interaction effect size at the missense SNP rs1801232 in
the CUBN gene in individuals of African ancestry, where the per-allele hazard ratio for T2D
was 2.78 (95% CI = 1.92, 4.03, p = 5.5 x 10−8) among smokers and 1.01 (95% CI = 0.58, 1.77,
p = 0.97) among non-smokers (pjoint = 1.3 x 10−7). Cubilin is a component of the vitamin
B12-intrinsic factor complex receptor in the ileal mucosa [53], and it is expressed in the apical
brush border of the renal proximal tubule, where it participates in receptor-mediated endocy-
tosis of low-molecular-weight proteins [54]. Defects in the CUBN gene have been associated
with both vitamin B12 deficiency and proteinuria, and the absence of cubilin results in the
autosomal recessive condition Imerslund-Gräsbeck syndrome, characterized by B12 malab-
sorption and variable levels of proteinuria from impaired renal protein reabsorption [55].
Mice heterozygous for CUBN deletion have increased albuminuria and decreased levels of
blood albumin and high-density lipoprotein (HDL) cholesterol [56]. The CKDGen consor-
tium meta-analysis identified a missense SNP in CUBN (rs18801239) associated with urinary
albumin/creatinine ratio and clinical microalbuminuria in the general population, an associa-
tion replicated in an AA cohort with type 1 diabetes [57] and later in the Framingham Off-
spring Study [58]. This SNP appears independent from the CUBN SNP identified in the
present analysis: in conditional analyses on rs18801239 in the discovery cohort, we found that
rs18801232 remained significantly associated with incident T2D among AA smokers only.
These CUBN observations point to plausible mechanisms, namely depressed levels of vitamin
B12 and HDL cholesterol, through which smoking might interact with cubilin to cause T2D.
Cigarette smoking impairs cubilin-mediated renal protein reabsorption through cadmium
and other contaminants, which form complexes with proteins that have high affinity for cubi-
lin and accumulate in the proximal tubule [59]. A mendelian randomization study found an
association between a genetic instrument for low vitamin B12 levels (including one CUBN var-
iant) and higher fasting glucose levels and lower pancreatic beta-cell secretory function, as
measured by HOMA-β, but not with higher odds of T2D [60]. Mendelian randomization stud-
ies have been inconsistent in whether genetic instruments for low HDL are associated with
increased T2D risk [61–64]. Whether CUBN defects and smoking interact to cause T2D
through these or other mechanisms merits further investigation.
We observed more modest potential interaction effects at four other SNPs. Among AA par-
ticipants, one SNP in FBN1 was associated with T2D only in smokers. The glycoprotein fibril-
lin-1 is a component of microfibrils in the extracellular matrix, which contribute to the
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elasticity of skin, blood vessels, and other tissues. Variants in FBN1 are associated with Marfan
syndrome, an autosomal dominant connective tissue disorder characterized by ocular, skeletal,
and cardiovascular abnormalities, including aortic dilatation and cardiac valve regurgitation
[65]. Among EA participants, one locus near C2orf63, which encodes a neurite outgrowth
inhibitor, was associated with T2D only in never smokers. This observation may suggest either
a protective role of smoking in the association of C2orf63 and T2D or an C2orf63-T2D associa-
tion otherwise obscured by the association between smoking and T2D. The two remaining loci
we identified were in TCF7L2, a gene whose well-established association with T2D was first
identified in 2006 and which remains the locus with the largest effect on T2D risk [66–68].
Variants in TCF7L2 are associated with decreased pancreatic beta-cell function [69,70] and
incretin sensitivity [71], and their association with increased proinsulin levels suggest defects
in insulin processing and secretion [72]. Experimental models support the role of TCF7L2 var-
iants in developmental beta cell proliferation, proinsulin processing, and insulin vesicle dock-
ing [73].
Examination of the functional genomic annotation of the GEWIS-significant SNPs gener-
ates novel biological hypotheses. For example, allele-specific differential gene expression
impacting glucose homeostasis in smokers versus non-smokers could explain the observed
potential gene-smoking interaction. A mechanism of interaction involving gene expression
would be consistent with all five statistically-significant SNPs being associated with regulatory
histone marks. Even the missense variant in the CUBN gene overlaps with regulatory annota-
tion in numerous tissues, including active enhancer histone marks in muscle, adipose, pan-
creas, and liver, and tags multiple DNA-binding protein sites. Similarly, the intergenic SNP at
the C2orf63 locus overlaps with both active enhancer and promoter histone marks from brain/
neural tissues. The intronic variant in the FBN1 gene overlaps with promoter and/or active
enhancer marks in brain, muscle, adipose, gastrointestinal tract, or pancreatic tissues. Finally,
each of the two intronic SNPs at the TCF7L2 locus has a slightly different pattern of regulatory
annotation. In addition, the pattern of regulatory marks overlapping the two TCF7L2 SNPs
identified in this study differs from the regulatory annotation related to the lead TCF7L2 SNP
associated in T2D case-control GWAS, suggesting multiple, potentially distinct regulatory
mechanisms underlying T2D in smokers and non-smokers. Further work is required to illumi-
nate how smoking might modify biologic pathways, including gene regulation, and may sug-
gest novel targets for diabetes therapy.
Prior studies of gene-smoking interaction for T2D risk have used a candidate gene
approach, focusing on loci associated either with smoking behavior, such as CYP2A6 [74] or
the nicotinic acetylcholine receptor gene (CHRNA4) [75], or with T2D and other metabolic
traits [76], including HNF1A [77] and APOC3 [78]. Our analyses did not replicate the findings
of these small candidate-gene studies at our predefined genome-wide significance thresholds,
highlighting unique contributions using unbiased GEWIS approaches. Limitations of our
study include the dichotomous categorization of the smoking exposure (ever vs. never), which
likely masks some of the effect of smoking dose and duration on our outcomes of interest.
Nonetheless, similar approaches have successfully identified gene-smoking interactions for
traits such as blood pressure [79], pulmonary function [80], and BMI [81]. Second, a locus
identified by the inclusion of a significant joint test as one criterion for potential locus-smok-
ing interaction may actually have a significant main effect, not a significant interaction with
smoking, if the inclusion of smoking in the model explained residual variability in the outcome
and increased power to detect main effects. To limit the impact of this misclassification, we
excluded SNPs with significant main effects from eligibility for this criterion. Third, although
we used data from about 75,000 individuals across the CHARGE Consortium Gene-Lifestyle
Interactions Working Group to replicate our discovery analyses, data from larger cohorts such
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as the UK Biobank and Million Veteran Program now exist and might provide future opportu-
nity for additional replication. Fourth, our discovery analyses only leveraged genotype data
from the IBC array available from the CARe Consortium; the use of increasingly available
sequencing data from large cohort studies might enable the detection of rare variants that
mediate the relationship between smoking and glycemic traits. Fifth, the lack of adequate
numbers of T2D cases in all sex/ancestry groups impeded adjustment for sex in some models.
It is unknown whether this lack of sex adjustment biased the results and, if so, the direction
and magnitude of effect. Larger studies in individuals of non-European ancestry are needed to
address this limitation.
Conclusions
We have demonstrated the feasibility and utility of GEWIS to identify potential gene-smoking
interactions in T2D risk. Future mechanistic study of the loci identified may help untangle the
complex relationship between the dual public health threats of T2D and smoking.
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66. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded Genome-Wide
Association Study of Type 2 Diabetes in Europeans. Diabetes. 2017; 66:2888–902. https://doi.org/10.
2337/db16-1253 PMID: 28566273.
67. Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of tran-
scription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics. 2006; 38:320–
3. https://doi.org/10.1038/ng1732 PMID: 16415884.
68. Flannick J, Mercader JM, Fuchsberger C, Udler MS, Mahajan A, Wessel J, et al. Exome sequencing of
20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019; 570(7759):71–6. Epub 2019/05/24.
https://doi.org/10.1038/s41586-019-1231-2 PMID: 31118516.
69. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, et al. TCF7L2 polymor-
phisms and progression to diabetes in the Diabetes Prevention Program. New England Journal of Medi-
cine. 2006; 355:241–50. https://doi.org/10.1056/NEJMoa062418 PMID: 16855264.
70. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by
which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;
117:2155–63. https://doi.org/10.1172/JCI30706 PMID: 17671651.
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